Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma

Journal of Clinical Oncology

Volumn 20, Issue 16, 2002, Pages 3533-3544

  Hughes, Andy ^a   Calvert, Paula ^a   Azzabi, Ashraf ^a   Plummer, Ruth ^a   Johnson, Rob ^a   Rusthoven, Jim ^a   Griffin, Melanie ^a   Fishwick, Kevin ^a   Boddy, Alan V ^a   Verrill, Mark ^a   Calvert, Hilary ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PEMETREXED;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HEMATOLOGIC DISEASE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; RASH; STOMATITIS; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUTAMATES; GUANINE; HEMATOLOGIC DISEASES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; SURVIVAL RATE;

EID: 20244374653     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.10.073     Document Type: Article

References (55)

1. The European mesothelioma epidemic
2. Malignant mesothelioma: Prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades 1965- 1985
3. Prognostic factors of malignant mesothelioma of the pleura
4. Malignant pleural mesothelioma: Multivariate analysis of prognostic factors on 113 patients
5. Diffuse malignant mesothelioma: Prospective evaluation of 69 patients
6. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: A retrospective study of 332 patients
7. Pleural fluid analysis in malignant mesothelioma: Prognostic implications
8. Structure-activity relationship studies of novel pyrrolopyrimidine antifolate LY231514
9. LY231514, a novel pyrrolopyrimidine antifolate that inhibits thymidylate synthase (TS)
10. LY231514, a pyrrolo [2,3-d] pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes
11. Activity of LY231514 against several enzymes in the folate-dependent pathways
12. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilising the modified continual reassessment method for dose escalation
13. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study
14. MTA (multitargeted antifolate, LY231514) in NSCLC patients who failed previous platinum or non-platinum chemotherapy: A phase II trial
15. Phase II study of first-line LY231514 (multitargeted antifolate) in patients with locally advanced or metastatic colorectal cancer: An NCIC Clinical Trials Group study
16. Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: Results from a phase II study
17. Phase II study of the multitargeted antifolate LY231514 (Alimta, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer
18. MTA (multitargeted antifolate, LY231514) in metastatic breast cancer patients (pts) with prior anthracycline exposure: A European phase II study
19. Pemetrexed disodium (Alimta, LY231514, MTA) in locally advanced or metastatic breast cancer patients with prior anthracycline or anthracenedione and taxane treatment: Phase II study
20. Phase II trial of MTA (LY231514) in advanced or recurrent squamous cell carcinoma of the head and neck
21. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin
22. Phase II study of ALIMTA (pemetrexed disodium, MTA) single agent in patients with malignant pleural mesothelioma
23. Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay
24. Carboplatin in malignant mesothelioma: A phase II study of the Cancer and Leukaemia Group B
25. Phase II trial of carboplatin (JM8) in the treatment of patients with malignant mesothelioma
26. Phase II trial of carboplatin in the management of malignant mesothelioma
27. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
28. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: A study of the Eastern Cooperative Oncology Group
29. Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II trial
30. Analysis of LY231514 in plasma and urine using perchloric acid with LC/MS/MS
31. A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve
32. The International Mesothelioma Interest Group: A proposed new International TNM staging system for malignant pleural mesothelioma
33. Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer
34. Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate LY231514
35. Vitamin B12 and folate reduce toxicity of Alimta™ (pemetrexed disodium, LY231514, MTA), a novel antifolate/antimetabolite
36. Sequence dependence using combinations of Alimta (pemetrexed disodium, LY231514, MTA), gemcitabine, and oxaliplatin in human colorectal carcinoma cell lines
37. The alpha folate receptor is highly activated in malignant pleural mesothelioma
38. Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: A phase II study
39. High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma
40. Treatment of malignant mesothelioma with methotrexate and vinblastine, with or without platinum therapy
41. The combination of raltitrexed ('Tomudex') and oxaliplatin is an active regimen in malignant mesothelioma: Results of a phase II study
42. Edatrexate (10-ethyldeaza-aminopterin) with or without leucovorin rescue for malignant mesothelioma: Sequential phase II trials by the Cancer and Leukemia Group B
43. Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B phase II study
44. Docetaxel for malignant mesothelioma: Phase II study of the Eastern Cooperative Oncology Group (ECOG 2595)
45. Phase II trial of single agent Taxotere (T) in malignant pleural mesothelioma (MPM)
46. CPT-11 in malignant mesothelioma: A phase II trial by the Cancer and Leukaemia Group B (CALGB 9733)
47. Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma: A feasibility study
48. Phase II study of vinorelbine in patients with malignant pleural mesothelioma
49. Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukaemia Group B
50. A phase II study of gemcitabine in patients with malignant pleural mesothelioma: European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group
51. Gemcitabine (Gemzar®) may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma
52. Multicentre phase II study of cisplatin and gemcitabine in malignant mesothelioma
53. Carboplatin and gemcitabine chemotherapy for malignant pleural mesothelioma: A phase II study of the GSTPV
54. Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: A pilot phase II clinical trial and pharmacokinetic profile
55. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first line therapy in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group